Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Enterprise Value (EV) 

Microsoft Excel

Current Enterprise Value (EV)

Vertex Pharmaceuticals Inc., current enterprise value calculation

Microsoft Excel
Current share price (P) $392.79
No. shares of common stock outstanding 256,390,651
US$ in thousands
Common equity (market value)1 100,707,684
Add: Preferred stock, $0.01 par value; none issued and outstanding (per books)
Total equity 100,707,684
Add: Current finance lease liabilities (per books) 5,200
Add: Long-term finance lease liabilities (per books) 112,800
Total equity and debt 100,825,684
Less: Cash and cash equivalents 4,569,600
Less: Marketable securities 1,546,300
Enterprise value (EV) 94,709,784

Based on: 10-K (reporting date: 2024-12-31).

1 Common equity (market value) = Share price × No. shares of common stock outstanding
= 392.79 × 256,390,651


Historical Enterprise Value (EV)

Vertex Pharmaceuticals Inc., EV calculation

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Share price1, 2 $462.58 $426.29 $297.40 $244.24 $210.50
No. shares of common stock outstanding1 256,789,869 258,307,816 257,091,441 254,576,691 259,960,062
US$ in thousands
Common equity (market value)3 118,785,858 110,114,039 76,458,995 62,177,811 54,721,593
Add: Preferred stock, $0.01 par value; none issued and outstanding (book value)
Total equity 118,785,858 110,114,039 76,458,995 62,177,811 54,721,593
Add: Current finance lease liabilities (book value) 5,200 50,600 40,800 46,900 42,434
Add: Long-term finance lease liabilities (book value) 112,800 376,100 430,800 509,800 539,042
Total equity and debt 118,903,858 110,540,739 76,930,595 62,734,511 55,303,069
Less: Cash and cash equivalents 4,569,600 10,369,100 10,504,000 6,795,000 5,988,187
Less: Marketable securities 1,546,300 849,200 274,500 729,900 670,710
Enterprise value (EV) 112,787,958 99,322,439 66,152,095 55,209,611 48,644,172

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Data adjusted for splits and stock dividends.

2 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.

3 2024 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 462.58 × 256,789,869


Common equity (market value) and Total equity
Both common equity (market value) and total equity exhibited a consistent upward trend over the five-year period. Starting at approximately $54.7 billion in 2020, equity rose steadily each year, reaching about $118.8 billion by the end of 2024. This represents more than a doubling of equity within the timeframe, indicating significant growth in the company's market valuation and shareholder equity base.
Total equity and debt
Total equity and debt followed a similar increasing pattern as total equity, beginning at roughly $55.3 billion in 2020 and growing to approximately $118.9 billion by 2024. The close alignment between total equity and total equity and debt values suggests that debt levels remained relatively modest compared to equity throughout the period. This stability implies a strong equity-funded capital structure.
Enterprise value (EV)
The enterprise value also showed substantial growth, increasing from around $48.6 billion in 2020 to about $112.8 billion in 2024. Although EV grew at a fast pace, the increase was slightly less pronounced than that of total equity and market value, potentially reflecting changes in debt levels or cash balances. Overall, the rising enterprise value mirrors the company’s expanding market capitalization and operational scale.
Overall financial trends
The data reflects strong growth over the five-year span in both equity and enterprise value. The consistent increase points to both enhanced investor confidence and effective capital management. The near parallel movement between total equity and total equity plus debt indicates prudent leverage control. This upward trajectory in key valuation metrics suggests favorable performance and growth prospects during the analysed period.